Overview
PGEN market data
Price History
PGEN price chart · 1M
- O
- 8.09
- H
- 8.25
- L
- 7.63
- C
- 7.76
- Vol
- 659,192.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $8.09
- Previous Close
- $7.70
- Day High
- $8.25
- Day Low
- $7.63
- 52 Week High
- $8.25
- 52 Week Low
- $3.52
- 7 Day Return
- -0.06%
- 30 Day Return
- +4.86%
- 90 Day Return
- +31.30%
- 1 Year Return
- +78.80%
- Daily Notional Volume
- $5.1M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.80 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.04 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -184.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.99 – $8.04 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.8B · P/B 70.73 · P/S 32.37.
Company News
10 captured
B. Riley Securities Initiates Coverage On Precigen with Buy Rating, Announces Price Target of $12Benzinga ·
Vertex Posts Positive Phase II Data on Kidney Disease DrugZacks Investment Research ·
FDA Accepts Insmed's Filing Seeking Label Expansion for ArikayceZacks Investment Research ·
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290Zacks Investment Research ·
Precigen Says FDA Granted Platform Technology Designation To AdenoVerse Immunotherapy PlatformBenzinga ·
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' SetbackZacks Investment Research ·
Definium Reports Second Phase III Success in Anxiety Disorder ProgramZacks Investment Research ·
Verastem Stock Skyrockets 121% in 3 Months: Here Is WhyZacks Investment Research ·
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally?Zacks Investment Research ·